Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) announced a collaboration with Grupo Fleury to expand clinical trial operations in Brazil through local services. Labcorp plans to introduce clinical trial kit assembly in early 2027, followed by laboratory operations expected to launch by the end of 2027. The laboratory operations remain in development.
Grupo Fleury will support the new operations, which will use Labcorp's global systems, processes and quality standards for multinational clinical trials. The collaboration extends Labcorp's clinical trial support capabilities across five continents, alongside its wholly owned central laboratory network in North America, Europe, Asia and Africa. Labcorp expects the Brazil operations to shorten kit delivery times, reduce reliance on international shipping and improve operational efficiency for trial sponsors.
Labcorp (NYSE: LH) announced that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10.
The fireside chat is scheduled for 8:45 a.m. ET. A live audio webcast will be available at ir.labcorp.com, with a replay archived for 180 days following the event.
Labcorp (NYSE: LH) reported third-quarter revenue of $3.81 billion and raised its full-year revenue growth and adjusted earnings guidance. Revenue rose 6.9% year over year. Diluted earnings per share increased to $3.22 from $3.12, while adjusted EPS, a non-GAAP measure, rose 14.5% to $4.78. Operating margin fell to 10.6% from 11.1%, but adjusted operating margin increased to 15.0% from 14.4%.
Labcorp now expects 2026 revenue growth of 5.9%–6.7% and adjusted EPS of $18.30–$18.70. Quarterly free cash flow increased to $412.2 million from $280.5 million. The company acquired MLM Medical Labs and signed agreements to acquire select BioReference Health assets, Myriad Genetics' Prenatal Health business and Millennium Health. The three pending acquisitions require regulatory approvals. Labcorp also received FDA approval for PGDx elio tissue complete CDx to help identify patients with advanced melanoma.
Labcorp (NYSE: LH) and Waters (NYSE: WAT) announced a partnership to expand access to FDA-approved HPV testing beginning in late 2026. The companies intend to offer the BD Onclarity HPV Assay through Labcorp's nationwide laboratory network by year-end, with clinician-collected and self-collected screening options in clinics, patient service centers and at home.
Labcorp will provide the testing through its clinician programs, Gaps in Care health plan programs and Labcorp OnDemand consumer channel. Its network serves more than 850,000 physicians and healthcare providers and includes more than 2,200 patient service centers. The assay identifies six HPV types individually and provides three grouped results for eight other types. The companies describe the collaboration as a way to address cervical cancer screening gaps.
Labcorp (NYSE: LH) announced a research collaboration with the FDA and Charles River Laboratories to improve methods for evaluating medicines' abuse potential.
The research will use a common behavioral economics methodology to quantify and rank abuse potential, meaning the likelihood that a medicine could be abused. Labcorp will contribute experience conducting regulatory abuse potential studies; FDA scientists will analyze data and contribute regulatory science expertise. The collaborators aim to generate evidence that may improve predictions of real-world use patterns and support drug development and regulatory decisions.
Labcorp has supported abuse potential evaluation studies since 2009, helping sponsors generate evidence for scheduling, labeling and other regulatory decisions.
Labcorp Holdings (NYSE: LH) announced that its board of directors has declared a cash dividend of $0.72 per common share. The dividend is payable on December 11, 2026, to stockholders of record as of the close of business on November 24, 2026.
Myriad Genetics (NASDAQ: MYGN) signed a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash. The purchase price also includes the business’s inventory value at closing. The sale covers the Prequel, Foresight, SneakPeek and FirstGene tests and is expected to close by early 2027, subject to regulatory clearance and customary closing conditions.
Myriad expects the transaction to improve its revenue growth and profitability and strengthen its balance sheet to support investment in cancer care priorities. The prenatal portfolio served over 600,000 patients over the last twelve months. Labcorp (NYSE: LH) expects approximately $160 million in revenue in year one, slight accretion to adjusted earnings in year one, and average diagnostics segment margins by the end of year two, once fully integrated.
Labcorp (LH) agreed with OPKO Health to acquire select BioReference Health assets for $722 million in cash at closing. The purchase covers clinical and women's health testing, urology, corrections and certain operational assets, including over 80 additional patient service centers. It also includes the FDA-approved 4Kscore Test, a blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision.
The closing price is subject to an upward or downward adjustment based on closing business revenues, with up to an additional $150 million payable based on 4Kscore Test revenue. Labcorp expects approximately $250 million in business revenue in the first year after closing. Regulatory approvals remain required. Until closing, operations and services will remain unchanged, and both companies will operate independently.
Labcorp (LH) launched the Thrive 5 Health Test with Thrive Global, pairing health testing with educational content and recommended daily actions.
The first lab test offered through this collaboration is available through Labcorp OnDemand. It covers cholesterol-related cardiovascular risk, inflammation, blood sugar, blood pressure and body mass index. Consumers can purchase the test and schedule testing at select Labcorp patient service centers nationwide. Results, Thrive Global educational content and recommended Thrive Microsteps are delivered through Labcorp's secure patient portal and MyLabcorp mobile app.
Labcorp Holdings (NYSE: LH) will release its third-quarter 2026 financial results before the market opens on October 28, 2026.
A webcast to discuss the results will begin at 9:00 a.m. ET that day. The results, accompanying financial information and webcast link will be available on its investor relations website. A webcast replay will be available afterward for one year.